Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound-Guided Inter-Sphincteric Botulinum Toxin A for Chronic Anal Fissure
2025-520748-13-01Phase 4Authorised
- Sponsor
- Hospital Universitario de Burgos
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in chronic anal fissure (CAF), sponsored by Hospital Universitario de Burgos. Primary endpoints: Pain intensity, Fecal incontinence severity and 2 more. Planned start Jan 2025; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on 2025-520748-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520748-13-01.